BERLIN – (July 4th, 2025) – Tesla BioHealing, a company using natural materials to create a biophoton-rich environment that promotes optimal well-being, shared at The Advances in Alternative & Molecular Medicine for Health compelling new findings on the efficacy of Biophoton Quantum Therapy for chronic pain reduction titled “Non-invasive Biophoton Therapy Significantly Reduces Chronic Pain – A Novel Alternative to Opioid Dependence.”

This keynote highlighted drug-free, energy-based therapeutic pathways to address opioid dependency.

“Our work shows a clear, non-toxic, and user-friendly path forward in chronic pain care,” said Dr. Liu, Founder and CEO of Tesla BioHealing. “Biophoton therapy addresses the root bioenergetic imbalance and offers real hope for patients seeking alternatives to opioids.”

Unlike conventional chemical-based medications, which often suppress symptoms and pose the risk of side effects or addiction, Biophoton Quantum Therapy operates on the principle that the human body is an interconnected energy field. This approach utilizes strong biophoton generators—non-invasive, over-the-counter devices that emit coherent light within the 500–1000 nm range—to stimulate natural healing processes.

Supported by real-world evidence from over 45,000 users, with a reported 97% improvement rate and zero adverse effects, the therapy has demonstrated significant potential in relieving severe pain. A recent open-label study involving 256 users showed marked improvement in SF-36 pain scores within one month of use. In a double-blind, placebo-controlled clinical trial (ClinicalTrials.gov ID: NCT06915012), patients with chronic arthritis pain reported substantial pain relief, with more data forthcoming.

Mechanistic studies suggest that biophoton therapy:

Enhances intercellular communication and energy flow

Reduces neuroinflammation

Stimulates mitochondrial ATP production

Activates the body’s endogenous opioid system—without drugs

Forward-Looking Statement

This press release contains forward-looking statements that involve certain risks and uncertainties. These statements include, but are not limited to, potential benefits of Tesla BioHealing® products. Factors that could cause actual results to differ materially include risks that clinical development activities may be delayed or unsuccessful, that products may not be approved or commercially viable and that regulatory decisions may be unfavorable. Tesla BioHealing Inc. and the First Institute of All Medicines (FIAM) disclaim any obligation to update these statements after the date hereof except as required by law.